TAIPEI, TAIWAN--(Marketwire - July 1, 2010) - The 2010 BioBusiness Asia (BBA) organized by the Industrial Technology Research Institute with the theme of "Energizing BioBusiness in Asia" will be held on July 20th-21st this year at Grand Hyatt, Taipei. Steven Burrill, CEO of the global healthcare venture capital firm Burrill & Company, recognized as "Warren Buffet" in the biotech investment area, will share his vision about biotech global trend and explore the development of biotech venture capital. In addition, Allen Chao, former CEO of Watson Pharmaceuticals, will share the key success factors in developing generic drugs market. Approximately 30 biotech and venture capital experts from China, Japan, U.S., Germany, Australia, and Taiwan will participate in BBA this year, exchanging current developments of the biotech industries in different countries. Over 23 major international biotech companies are expected to participate the one-on-one "Business to Business Partnering" session. The session is a great opportunity for venture capitalists to network with the biotechnology businesses in Taiwan and explore collaborative opportunities with Asian biotech companies.
Since 2002, BBA has been successfully attracting elites from the biotech industry, and has become the largest biotech business information exchange and meeting platform in Asia. The conference will feature keynote speeches on topics of emerging biotech global trends, business models and the strategies to leverage global resources. There is an Investor and Business Partnering Session to facilitate one-on-one networking among participants. Experts will also provide the insights for the future biotech business opportunities in Taiwan and Greater China.
For international participants who would like to register BBA, please contact Ms. Wendy Tsai, Tel: 886-35912457, E-mail: wendytsai@itri.org.tw. For more information, please visit www.biobusiness-asia.com/2010/.
About ITRI (www.itri.org.tw/eng)
The Industrial Technology Research Institute (ITRI) is a nonprofit R&D organization engaging in applied research and technical services. Founded in 1973, ITRI has played a vital role in transforming Taiwan's economy from a labor-intensive industry to a high-tech industry. Numerous well-known, high-tech companies in Taiwan, such as leaders in the semiconductor industry TSMC and UMC, can trace their origins to ITRI.
Innovative Research
ITRI is a multidisciplinary research center, with six core laboratories, five focus centers, five linkage centers, several leading labs and various business development units. The six fields ITRI focuses on include Information and Communication; Electronics and Optoelectronics; Material, Chemical and Nanotechnologies; Biomedical Technologies; Advanced Manufacturing and Systems; and Energy and Environment. ITRI has aggressively researched and developed countless next-generation technologies, including WIMAX wireless broadband, solar cells, RFID, light electric vehicles, flexible displays, 3-D ICs and telecare technologies. In addition, ITRI's Flexible Electronics Pilot Lab and Nanotechnology Lab provide international-level research platforms where R&D can be conducted jointly with partners. ITRI has also seen significant growth in intellectual property business and new ventures in recent years and is devoted to creating a model that would make Taiwan manufacturing even more competitive in the international arena.
Fostering Entrepreneurship and CEO Leadership
ITRI employs around 5,800 personnel, including 1,131 who hold Ph.D.s and 3,190 with master's degrees, resulting in an average of five patents produced every day. By disseminating both technology and talent, ITRI has led the technology industry into the 21st century and has cultivated 70 CEOs in the local high-tech industry. In addition to its headquarters in Taiwan, ITRI has branch offices in the California Silicon Valley, Tokyo, Berlin and Moscow.
Contact Information:
Media Contact:
Kristie Lee
ITRI, Office of Marketing Communications
Tel: +886-3-5919392